Bayer AG (BAYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
223
About the Report
About the Report
Summary
Bayer AG (Bayer) carries out the research, development, production and commercialization of products for human and animal health care, and agriculture. It provides medicines for cardiovascular diseases, women's health, cancer, hematology, ophthalmology and other indications. The company's product portfolio includes prescription products, specialty therapeutics, animal health care products, diagnostic imaging equipment, nonprescription (over-the-counter-OTC) products, seeds, crop protection solutions and nonagricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, Germany.
Bayer AG (BAYN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Bayer AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 8
Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10
Bayer AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11
Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12
Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13
Bayer AG, Medical Devices Deals, 2012 to YTD 2018 15
Bayer AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16
Bayer AG, Pharmaceuticals & Healthcare, Deal Details 20
Asset Purchase 20
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 20
Venture Financing 22
BlueRock Therapeutics Raises USD225 Million in Series A Financing 22
Private Equity 23
Bayer to Raise USD3.69 Billion in Private Placement of Shares 23
Bayer May Sell Dermatology Business 25
Sobera Capital Acquires Minority Stakes In Biopharma Companies From Bayer Pharma And Bayer HealthCare 26
Partnerships 27
ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 27
Bayer and MD Anderson Cancer Center Enter into Agreement 28
Bayer and PeptiDream Enter into Partnership 29
Bayer Enters into Co-Development Agreement with Loxo Oncology 30
Bayer and Vanderbilt University Medical Center Enter into Research Agreement 31
leadXpro Enters into Agreement with Bayer 32
University of Pittsburgh and Bayer Form Research Collaboration Agreement 33
Bayer Enters into Partnership with Evotec 34
Bayer Enters into Agreement with National Surgical Adjuvant Breast and Bowel Project 35
Bayer Enters into Co-Development Agreement with Regeneron Pharma 36
Bayer and CRISPR Therapeutics Forms Joint Venture 37
Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 38
Proteros Biostructures Enters into Research Agreement with Bayer 39
Bayer HealthCare Enters Co-Development Agreement with University of Oxford 40
Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 41
arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 42
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 43
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 44
Bayer HealthCare Pharma And Broad Institute Enter Into Agreement To Develop Cancer Therapy 45
Bayer Enters Into Co-Marketing Agreement With Ildong Pharma For OTC Drugs 46
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 47
Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 48
X-Chem and Bayer Pharma Expand Agreement 49
Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 50
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 51
Algeta Exercises Option Agreement With Bayer To Co-Promote Alpharadin 53
Bayer Healthcare Enters Into Co-Development Agreement With Tsinghua University 54
Licensing Agreements 55
Bayer Enters into Licensing Agreement with Haplogen and Evotec 55
Luye Pharma and Luye Supply to Enter into Agreement with Bayer 56
Bayer Enters into Licensing Agreement with Progenics Pharma 57
X-Chem Enters into Licensing Agreement with Bayer Pharma for Drug Discovery Program 58
Taisho Pharma Enters into Licensing Agreement with Bayer Yakuhin 59
Bayer Enters into Licensing Agreement with ERS Genomics 60
Bayer Pharma Enters Into Licensing Agreement With X-Chem For Drug Discovery Program 61
Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 62
Oxford Pharmascience Enters Into Licensing Agreement With Bayer Consumer Care 63
Equity Offering 64
Bayer Plans to Raise USD7 Billion in Rights Offering of Shares 64
Crispr Therapeutics Prices Private Placement of Shares for USD35 Million 65
Debt Offering 66
Bayer to Raise USD2.5 Billion in Private Placement of 4.25% Bonds Due 2025 66
Bayer to Raise USD1.74 Billion in Private Placement of 2.125% bonds Due 2029 67
Bayer to Raise USD1.25 Billion in Private Placement of 3.5% Bonds Due 2021 68
Bayer to Raise USD2 Billion in Private Placement of 4.875% Bonds Due 2048 69
Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2021 70
Bayer to Raise USD3.5 Billion in Private Placement of 4.375% Bonds Due 2028 71
Bayer to Raise USD2.03 Billion in Private Placement of 1.5% bonds Due 2026 72
Bayer to Raise USD2.25 Billion in Private Placement of 3.875% Bonds Due 2023 73
Bayer to Raise USD1 Billion in Private Placement of 4.625% Bonds Due 2038 74
Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2023 75
Bayer to Raise USD870 Million in Private Placement of Bonds Due 2022 76
Bayer to Raise USD1.16 Billion in Private Placement of 0.625% bonds Due 2022 77
Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 78
Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 79
Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 80
Bayer Raises USD1.5 Billion in Public Offering of 3% Bonds Due 2021 81
Bayer Raises USD2 Billion in Public Offering of 2.375% Bonds Due 2019 82
Bayer Raises USD500 Million in Public Offering of Notes Due 2016 83
Bayer Raises USD400 Million in Public Offering of Bonds Due 2017 84
Bayer Raises USD1.75 Billion in Public Offering of 3.375% Bonds Due 2024 85
Bayer Raises USD850 Million in Public Offering of 1.5% Bonds Due 2017 86
Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 87
Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 89
Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 91
Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 92
Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 93
Bayer Completes Public Offering Of Notes Due 2019 For USD 102 Million 94
Bayer Completes Public Offering Of Notes Due 2016 For USD 259 Million 95
Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For USD 363 Million 96
Asset Transactions 97
LEO Pharma Acquires Prescription Dermatology Portfolio from Bayer 97
Recordati Acquires Consumer Health Brands from Bayer Consumer Care 98
Famar Health Care Services Acquires Pointe-Claire Manufacturing Site from Bayer 99
WellSpring Pharma Acquires Bactine 100
Alvogen Acquires Five Hormonal Products from Bayer Pharma 101
Bayer Korea to Sell Mercilon 102
Alliance Pharma Acquires Rights To Irenat From Bayer 103
Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For USD 4.8 Million 104
Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 105
Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 106
Acquisition 107
Bayer to Acquire Minority Stake in CRISPR Therapeutics for USD35 Million 107
Bayer Acquires Dihon Pharma for USD586 Million 108
Bayer Nordic Completes Acquisition Of Algeta For USD 2.58 Billion 109
Bayer Completes Acquisition Of Steigerwald Arzneimittelwerk, Herbal Treatments Provider 111
Bayer Completes Acquisition Of 96.4% Stake In Conceptus For USD 1.1 Billion 112
Delpharm Completes Acquisition Of Bayer Sante Familiale, Consumer Care Division Of Bayer 114
Nomad Bioscience Acquires Icon Genetics From Bayer Innovation 115
Bayer AG-Key Competitors 116
Bayer AG-Key Employees 117
Bayer AG-Locations And Subsidiaries 118
Head Office 118
Other Locations & Subsidiaries 118
Joint Venture 127
Recent Developments 129
Financial Announcements 129
May 03, 2018: Bayer: Operational business held back by currency effects – Major progress with Monsanto acquisition 129
Oct 26, 2017: Bayer: Sales and earnings increased 133
Apr 27, 2017: Strong start to the year for Bayer 138
Corporate Communications 141
Sep 27, 2018: Bayer appoints Sebastian Guth to lead Pharmaceuticals business in the Americas 141
Sep 13, 2018: Bayer appointed Stefan Oelrich to Board of Management 142
Nov 15, 2017: Heiko Schipper is the new CEO and Head of the Consumer Health Division at Bayer 144
Sep 29, 2017: Bayer helping people affected by the earthquake in Mexico 145
Sep 12, 2017: Wolfgang Nickl to be new Chief Financial Officer at Bayer 146
Apr 27, 2017: Supervisory Board of Bayer extends service contract of CFO Johannes Dietsch to the end of May 2018 147
Jan 17, 2017: Dr. Carsten Brunn to Lead Bayer's Pharmaceuticals Business in the Americas Region 148
Legal and Regulatory 149
Sep 21, 2018: NHS wins landmark ruling against pharma companies over AMD drug 149
Aug 22, 2017: Bayer will continue to work constructively with the European Commission 150
Government and Public Interest 151
Mar 28, 2018: Life Science Leaders Gather at Medidata NEXT Basel and Frankfurt to Examine New Opportunities to Improve Clinical Development and Better Patient Lives 151
Nov 17, 2017: Christine Eischen Receives 2017 AACR-Bayer Innovation and Discovery Grant 152
Jul 18, 2017: Two Indian researchers win Grants to advance Hemophilia Research & Care 153
Jul 11, 2017: Bayer Awards $2 Million in Grants to Advance Hemophilia Research and Patient Care 155
Feb 22, 2017: Another record year for Bayer – good progress with the acquisition of Monsanto 156
Product News 160
12/07/2017: Bayer to Highlight New Research on copanlisib at ASH 2017 160
11/01/2017: Janssen to Present Abstracts on XARELTO at ASH 2017 161
10/30/2017: Bayer receives FDA approval for Xarelto 10 mg once daily for the extended treatment of venous thromboembolism 165
10/25/2017: Study: Rx Drug Lawsuit Ads Cause Spike in Reports of Patient Health Incidents, Deaths 166
09/15/2017: Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism 167
09/14/2017: Bayer Receives FDA Approval for Aliqopa (copanlisib) 60 mg vial for Injection in Adults with Relapsed Follicular Lymphoma after Two Prior Systemic Therapies 169
08/22/2017: Landmark GARFIELD-AF Data to be Presented at ESC 2017 Congress Will Feature 1-year Outcomes on 52,000 Prospective Patients and the First Insights From the Registry on Health Economics in Atrial Fibrillation (AF) 170
07/26/2017: Compugen Provides Update on its Immuno-Oncology Drug Candidate CGEN-15001T 173
07/21/2017: Bayer’s Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement 174
07/02/2018: Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254 176
06/28/2017: U.S. FDA Grants Priority Review of XARELTO (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism 177
05/17/2018: Bayer to Present One Poster on Rogaratinib at ASCO 2018 179
05/17/2017: Bayer Receives FDA Priority Review For Investigational Anti-Cancer Compound Copanlisib 180
03/18/2017: Bayer's Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study 182
Product Approvals 184
Dec 11, 2017: Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD) 184
Nov 06, 2017: Bayer Submits Application for Marketing Approval of Rivaroxaban for Patients with Coronary or Peripheral Artery disease to European Medicines Agency 185
Apr 28, 2017: Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism 187
Clinical Trials 189
Oct 09, 2018: Bayer to showcase latest oncology research on copanlisib at ESMO 2018 Congress 189
May 17, 2018: Bayer to Present on Copanlisib Hydrochloride at ASCO 2018 190
Apr 18, 2018: Evotec and Bayer advance third endometriosis programme into Phase I clinical development 191
Apr 17, 2018: Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy 192
Dec 07, 2017: Thirteen abstracts highlighting data from Bayer's rivaroxaban will be presented at ASH 2017, two addressing cancer-associated thrombosis 193
Nov 10, 2017: Bayer’s Xarelto(rivaroxaban) Significantly Reduces the Risk of Major Amputation by 70% in Patients with Peripheral Artery Disease 195
Oct 05, 2017: Bayers NAVIGATE ESUS study halted early as it indicated comparable efficacy between treatment arms 196
Sep 01, 2017: Bayer to Present Data on Copanlisib at ESMO 2017 Congress 197
Sep 01, 2017: Bayer to Present Data on Rogaratinib at ESMO 2017 Congress 198
Aug 27, 2017: Bayer's Xarelto significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or peripheral artery disease by 24% 199
Aug 21, 2017: New XARELTO (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study 201
Jul 24, 2017: Evotec and Bayer Advance Endometriosis Programme into Phase I Clinical Development and Extend Alliance 207
Jul 03, 2017: New Data from Bayers Portfolio in Thrombosis and Hemophilia to be Presented at ISTH 2017 208
Mar 31, 2017: Phase II Copanlisib Data Show Durable Tumor Response in Indolent Non-Hodgkin’s Lymphoma 210
Mar 06, 2017: EINSTEIN CHOICE Study with Bayer's Rivaroxaban Accepted for Late-Breaking Clinical Trial Presentation at ACC.17 212
Feb 08, 2017: Phase III COMPASS study with Bayer's Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early 215
Other Significant Developments 217
Oct 17, 2018: Bayer provides disaster reliefImmediate support for earthquake victims in Indonesia company makes EUR 115,000 available in immediate assistance for people impacted in Central Sulawesi province 217
Aug 30, 2018: Bayer accelerates six new startups 218
May 31, 2018: ORNL ramps up production of key radioisotope for cancer-fighting drug 219
Dec 01, 2017: Bayer invests in differentiated drug pipeline with over 50 projects focused on high unmet medical needs 220
Appendix 223
Methodology 223
About GlobalData 223
Contact Us 223
Disclaimer 223
List of Figure
List of Figures
Bayer AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10
Bayer AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 11
Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12
Bayer AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 13
Bayer AG, Medical Devices Deals, 2012 to YTD 2018 15
List of Table
List of Tables
Bayer AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Bayer AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 10
Bayer AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 11
Bayer AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 12
Bayer AG, Deals By Therapy Area, 2012 to YTD 2018 13
Bayer AG, Medical Devices Deals, 2012 to YTD 2018 15
Bayer AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 16
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 20
BlueRock Therapeutics Raises USD225 Million in Series A Financing 22
Bayer to Raise USD3.69 Billion in Private Placement of Shares 23
Bayer May Sell Dermatology Business 25
Sobera Capital Acquires Minority Stakes In Biopharma Companies From Bayer Pharma And Bayer HealthCare 26
ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 27
Bayer and MD Anderson Cancer Center Enter into Agreement 28
Bayer and PeptiDream Enter into Partnership 29
Bayer Enters into Co-Development Agreement with Loxo Oncology 30
Bayer and Vanderbilt University Medical Center Enter into Research Agreement 31
leadXpro Enters into Agreement with Bayer 32
University of Pittsburgh and Bayer Form Research Collaboration Agreement 33
Bayer Enters into Partnership with Evotec 34
Bayer Enters into Agreement with National Surgical Adjuvant Breast and Bowel Project 35
Bayer Enters into Co-Development Agreement with Regeneron Pharma 36
Bayer and CRISPR Therapeutics Forms Joint Venture 37
Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 38
Proteros Biostructures Enters into Research Agreement with Bayer 39
Bayer HealthCare Enters Co-Development Agreement with University of Oxford 40
Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 41
arGEN-X Enters into Agreement with Bayer Pharma To Discover and Develop Therapeutic Antibody Candidates 42
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 43
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 44
Bayer HealthCare Pharma And Broad Institute Enter Into Agreement To Develop Cancer Therapy 45
Bayer Enters Into Co-Marketing Agreement With Ildong Pharma For OTC Drugs 46
Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 47
Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 48
X-Chem and Bayer Pharma Expand Agreement 49
Horizon Discovery Enters Into Co-Development Agreement With Bayer Pharma For Human Isogenic Cell Lines 50
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 51
Algeta Exercises Option Agreement With Bayer To Co-Promote Alpharadin 53
Bayer Healthcare Enters Into Co-Development Agreement With Tsinghua University 54
Bayer Enters into Licensing Agreement with Haplogen and Evotec 55
Luye Pharma and Luye Supply to Enter into Agreement with Bayer 56
Bayer Enters into Licensing Agreement with Progenics Pharma 57
X-Chem Enters into Licensing Agreement with Bayer Pharma for Drug Discovery Program 58
Taisho Pharma Enters into Licensing Agreement with Bayer Yakuhin 59
Bayer Enters into Licensing Agreement with ERS Genomics 60
Bayer Pharma Enters Into Licensing Agreement With X-Chem For Drug Discovery Program 61
Bayer Pharma Enters Into Licensing Agreement With Dyax For Human Antibody Phage Display Library 62
Oxford Pharmascience Enters Into Licensing Agreement With Bayer Consumer Care 63
Bayer Plans to Raise USD7 Billion in Rights Offering of Shares 64
Crispr Therapeutics Prices Private Placement of Shares for USD35 Million 65
Bayer to Raise USD2.5 Billion in Private Placement of 4.25% Bonds Due 2025 66
Bayer to Raise USD1.74 Billion in Private Placement of 2.125% bonds Due 2029 67
Bayer to Raise USD1.25 Billion in Private Placement of 3.5% Bonds Due 2021 68
Bayer to Raise USD2 Billion in Private Placement of 4.875% Bonds Due 2048 69
Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2021 70
Bayer to Raise USD3.5 Billion in Private Placement of 4.375% Bonds Due 2028 71
Bayer to Raise USD2.03 Billion in Private Placement of 1.5% bonds Due 2026 72
Bayer to Raise USD2.25 Billion in Private Placement of 3.875% Bonds Due 2023 73
Bayer to Raise USD1 Billion in Private Placement of 4.625% Bonds Due 2038 74
Bayer to Raise USD1.25 Billion in Private Placement of Bonds Due 2023 75
Bayer to Raise USD870 Million in Private Placement of Bonds Due 2022 76
Bayer to Raise USD1.16 Billion in Private Placement of 0.625% bonds Due 2022 77
Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 78
Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 79
Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 80
Bayer Raises USD1.5 Billion in Public Offering of 3% Bonds Due 2021 81
Bayer Raises USD2 Billion in Public Offering of 2.375% Bonds Due 2019 82
Bayer Raises USD500 Million in Public Offering of Notes Due 2016 83
Bayer Raises USD400 Million in Public Offering of Bonds Due 2017 84
Bayer Raises USD1.75 Billion in Public Offering of 3.375% Bonds Due 2024 85
Bayer Raises USD850 Million in Public Offering of 1.5% Bonds Due 2017 86
Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 87
Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 89
Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 91
Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 92
Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 93
Bayer Completes Public Offering Of Notes Due 2019 For USD 102 Million 94
Bayer Completes Public Offering Of Notes Due 2016 For USD 259 Million 95
Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For USD 363 Million 96
LEO Pharma Acquires Prescription Dermatology Portfolio from Bayer 97
Recordati Acquires Consumer Health Brands from Bayer Consumer Care 98
Famar Health Care Services Acquires Pointe-Claire Manufacturing Site from Bayer 99
WellSpring Pharma Acquires Bactine 100
Alvogen Acquires Five Hormonal Products from Bayer Pharma 101
Bayer Korea to Sell Mercilon 102
Alliance Pharma Acquires Rights To Irenat From Bayer 103
Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For USD 4.8 Million 104
Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 105
Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 106
Bayer to Acquire Minority Stake in CRISPR Therapeutics for USD35 Million 107
Bayer Acquires Dihon Pharma for USD586 Million 108
Bayer Nordic Completes Acquisition Of Algeta For USD 2.58 Billion 109
Bayer Completes Acquisition Of Steigerwald Arzneimittelwerk, Herbal Treatments Provider 111
Bayer Completes Acquisition Of 96.4% Stake In Conceptus For USD 1.1 Billion 112
Delpharm Completes Acquisition Of Bayer Sante Familiale, Consumer Care Division Of Bayer 114
Nomad Bioscience Acquires Icon Genetics From Bayer Innovation 115
Bayer AG, Key Competitors 116
Bayer AG, Key Employees 117
Bayer AG, Subsidiaries 118
Bayer AG, Joint Venture 127
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.